coadministered cagrilintide and semaglutide in adults with overweight or obesity NEJM on X: "In the REDEFINE 2 phase 3a trial involving diabetes, the use of cagrilintide–semaglutide resulted a significantly lower body weight than placebo at 68 weeks Cagrilintide is an amylin analogue

Administration: Subcutaneous injection represents the standard route for both peptides

Mixing them creates stability and degradation issues that compromise the efficacy of both compounds

Using a compound from an unvetted source introduces risks that are simply not worth taking

Significant appetite suppression

A label reading Dihexa, PNB-0408, ATH-1001, or Dihexa acetate does not establish which substance or salt is presentor its concentration, purity, sterility, stability, or handling

Schema markup for calculators: I added basic WebApplication schema, but it's unclear how much Google actually uses calculator-specific schema